Fuse today announced it has raised £1 million to accelerate commercialisation of its proprietary Flip™ product platform and expand manufacturing capabilities at its headquarters in Cambridge, UK.

Fuse Diagnostics Ltd (Fuse) has today announced a significant expansion in its market presence following the signing of a number of distribution agreements in key target markets for it’s Flip product range.

Fuse Diagnostics (Fuse) has today announced that it has launched Flip Mycoplasma in Europe and signed a distribution agreement with CliniSciences covering major European countries, including France, Germany, Spain and Italy.

Fuse Diagnostics and Stratech Scientific have today announced a strategic distribution partnership for the commercialisation of Flip Mycoplasma in the UK and Ireland. 

First product Flip Mycoplasma detects cell culture contamination with unrivalled speed, accuracy and simplicity

Award to fund development and characterization of assays for Chlamydia trachomatis and Neisseria gonorrhoeae to integrate into low-cost, instrument-free diagnostic.

Fuse Diagnostics has today announced that it has completed an oversubscribed seed investment round – raising a total of £1.6 million from a syndicate of angel investors and innovation agency Innovate UK.